Skip to content

Study · Not a test of the peptide alone · 1996

3 results

The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment.

Hugosson J, Abrahamsson PA, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M, Pedersen K

European urology1 Jan 1996Cited by 31 (Europe PMC)

PMID8791047 (opens in a new tab)DOI10.1159/000473789 (opens in a new tab)PepBankPUB-08791047
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In prostate cancer, preoperative triptorelin plus cyproterone acetate did not change blood loss versus immediate surgery.

    In plain wordsIn prostate cancer, blood loss was similar with preoperative triptorelin plus cyproterone acetate and immediate surgery.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePeri-operative blood loss
    Study

    n = 111

    Comparator
    Immediate radical prostatectomy
    Outcome group
    Surgical outcomes · Cancer

    Source sentences

    Summary
    No differences were found in blood loss or operation time but patients who had neo-adjuvant treatment had a significantly lower frequency of positive margins (41 vs. 23%, p = 0.013).
    1 context sentence
    Summary · context
    Of 111 surgically treated patients with prostate cancer (T1b-T3a, N0, M0, G1-3), 55 were randomised to immediate radical prostatectomy and 56 to 3 months of neo-adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks to prevent flare).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In prostate cancer, preoperative triptorelin plus cyproterone acetate did not change operation time versus immediate surgery.

    In plain wordsIn prostate cancer, operation time was similar with preoperative triptorelin plus cyproterone acetate and immediate surgery.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOperation time
    Study

    n = 111

    Comparator
    Immediate radical prostatectomy
    Outcome group
    Surgical outcomes · Cancer

    Source sentences

    Summary
    No differences were found in blood loss or operation time but patients who had neo-adjuvant treatment had a significantly lower frequency of positive margins (41 vs. 23%, p = 0.013).
    1 context sentence
    Summary · context
    Of 111 surgically treated patients with prostate cancer (T1b-T3a, N0, M0, G1-3), 55 were randomised to immediate radical prostatectomy and 56 to 3 months of neo-adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks to prevent flare).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In prostate cancer, preoperative triptorelin plus cyproterone acetate reduced positive margins to 23% versus 41% with immediate surgery.

    In plain wordsIn prostate cancer, positive margins were less frequent with preoperative triptorelin plus cyproterone acetate than with immediate surgery.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePositive surgical margins
    Study

    n = 111

    Comparator
    Immediate radical prostatectomy
    Outcome group
    Tumor growth · Cancer

    Measurements

    Positive surgical margins
    41%
    immediate radical prostatectomy
    Positive surgical margins
    23%
    neo-adjuvant triptorelin plus cyproterone acetate

    Source sentences

    Summary
    No differences were found in blood loss or operation time but patients who had neo-adjuvant treatment had a significantly lower frequency of positive margins (41 vs. 23%, p = 0.013).
    1 context sentence
    Summary · context
    Of 111 surgically treated patients with prostate cancer (T1b-T3a, N0, M0, G1-3), 55 were randomised to immediate radical prostatectomy and 56 to 3 months of neo-adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks to prevent flare).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.